← All trials
NCT04658680
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Dec 8, 2020
- Last posted
- Feb 26, 2021
- Enrollment
- 22800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bandim Health ProjectLead sponsor
- Bandim Health ProjectStudy director
- University of Southern DenmarkCollaborator
- University Hospital Bispebjerg and FrederiksbergStudy director
- University of Southern DenmarkOverall official - principal investigator
- University of Southern DenmarkStudy director
- University of CopenhagenStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.